Trial reportFrontiers in endocrinology2025
Efficacy and safety of needle-free injection in patients with type 2 diabetes mellitus undergoing intensive insulin therapy: a randomized controlled trial based on the flash glucose monitoring system.
Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This randomized, open-label, parallel-controlled trial investigated the efficacy and safety of needle-free injection (NFI) compared to conventional insulin pen (CIP) in patients with type 2 diabetes mellitus (T2DM) undergoing intensive insulin therapy. A total of 64 hospitalized patients were randomly assigned to receive either NFI or CIP as part of a basal-bolus insulin regimen for 12 ± 2 days. Glycemic parameters were continuously monitored using a flash glucose monitoring (FGM) system. The NFI group showed significantly greater reductions in fasting plasma glucose (FPG) and 2-hour postprandial glucose (2hPPG), along with a more pronounced increase in serum 1,5-anhydroglucitol (1,5-AG) levels compared to the CIP group (all P < 0.05). Glycemic variability was also reduced in the NFI group, as indicated by higher time in range (TIR) and lower mean amplitude (MAGE) and largest amplitude (LAGE) of glycemic excursions (P < 0.05). Participants in the NFI group reached glycemic targets faster than those in the CIP group (1.88 ± 1.36 vs. 2.94 ± 1.59 days, P < 0.05), while daily insulin requirements remained comparable. Furthermore, the NFI group reported fewer injection-site adverse reactions, significantly lower pain scores, and higher treatment satisfaction (P < 0.001), with no increase in hypoglycemic events. These findings suggest that needle-free injection is a safe and effective alternative to conventional insulin delivery in hospitalized patients with T2DM, offering improved glycemic control, reduced glucose variability, and enhanced treatment experience. Clinical Trial Registration: identifier ChiCTR1900022412.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.